Andrew D. Mosholder

Statistics

Publications

Citations

561

H-Index

Active since

2006

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Harvard Pilgrim Health Care

Stanford University

Harvard University

Andrew D. Mosholder is an author at United States Food and Drug Administration specializing in pharmacotherapy, pharmacoepidemiology, and psychopharmacology.

ORCID

Publications per year

2006–2022

Publications

An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system

Eric Colman, Ana Szarfman, Jo Wyeth et al. · Pharmacoepidemiology and Drug Safety · 2008 · 58 citations

Pharmacy, Neurology, Pharmacology +17

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors

Christopher G. Rowan, Allen Brinker, Parivash Nourjah et al. · Pharmacoepidemiology and Drug Safety · 2009 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Risk of Psychiatric Adverse Events Among Montelukast Users

Veronica Sansing‐Foster, Nicole Haug, Andrew D. Mosholder et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 53 citations

Medicine, Pharmacotherapy, Psychiatry +13

Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions

Carol Pamer, Tarek A. Hammad, Yute Wu et al. · Pharmacoepidemiology and Drug Safety · 2010 · 49 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Neuropsychiatric events in varenicline and nicotine replacement patch users in the <scp>M</scp> ilitary <scp>H</scp> ealth <scp>S</scp> ystem

Tamra E. Meyer, Lockwood G. Taylor, Suji Xie et al. · Addiction · 2012 · 45 citations

Medicine, Pharmacotherapy, Psychiatry +15

1–5 of 18